ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO1009

Renal Microvascular Inflammation in Human Obesity Detected by Urinary Extracellular Vesicles

Session Information

Category: CKD (Non-Dialysis)

  • 2303 CKD (Non-Dialysis): Mechanisms


  • Al Saeedi, Mina H., Mayo Clinic Research Rochester, Rochester, Minnesota, United States
  • Jordan, Kyra L., Mayo Clinic Research Rochester, Rochester, Minnesota, United States
  • Zhu, Xiang yang, Mayo Clinic Research Rochester, Rochester, Minnesota, United States
  • Eirin, Alfonso, Mayo Clinic Research Rochester, Rochester, Minnesota, United States
  • Lerman, Lilach O., Mayo Clinic Research Rochester, Rochester, Minnesota, United States

Obesity is characterized by systemic inflammation and activation of the inflammatory marker monocyte chemoattractant protein (MCP)-1, but the involvement of inflammation in early renal injury is unclear. Plasmalemmal vesicle-associated protein (PLVAP), a marker of renal peritubular capillaries, is upregulated in diabetes. We hypothesized that human obesity induces renal microvascular inflammation detectable by elevated levels of PLVAP+/MCP-1+ urinary extracellular vesicles (uEVs).


Obese patients (OB, n=6) and healthy volunteers (HV, n=7) were prospectively enrolled. Blood and urine were collected, and uEVs were isolated (Total Exosome). uEVs were quantified (Nanoparticle Tracking Analysis) and characterized (Flow cytometry) for CD31, PLVAP, CD144 (expressed on glomerular endothelium), and MCP-1, and their relationship with body mass index (BMI) and serum glucose levels was evaluated.


OB had significantly higher BMI than HV, but both groups showed preserved renal function and glucose levels (Table-1), and a similar number and size of uEV. However, the fraction of CD31-/PLVAP+/CD144-/MCP-1+ was higher in OB and directly correlated with both glucose levels and BMI in OB but not in HV (Figure-1).


Non-diabetic obese patients show elevated numbers of PLVAP+/MCP-1+ uEVs that correlate with BMI and glucose levels. These early markers of renal microvascular inflammation that herald the development of pre-diabetes might be useful in the management of patients with obesity.

Demographics (mean± standard deviation (SD) or median(min,max))
Age, Yrs.46 ± 1245 ± 10
Sex, M/F1/60/6
BMI, Kg/m226.3 ± 2.546.4 ± 8.2*
Serum Creatinine, mg/dl0.84 ± 0.130.67 ± 0.15
eGFR, ml/min/1.73m290 (90,81)89 (85,90)
Serum Glucose, mg/dl100 ± 7.7101 ± 19

*P<0.05 vs. HV



  • NIDDK Support